Back to search
Antibody-Mediated Rejection
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Antibody-Mediated Rejection trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Antibody-Mediated Rejection trials you may qualify forThe primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with ac…
The purpose of this study is to assess the safety, tolerability, and efficacy of efgartigimod PH20 SC given by a prefilled syringe in participants with Antibody…
Humoral rejection of kidney transplants is responsible for a large number of kidney graft losses in a context of increasing shortage. Although it has been esta…
In this study, researchers will learn more about the use of felzartamab in kidney transplant patients who have antibody-mediated rejection, also known as AMR. K…
Chronic AntiBody-Mediated Rejection (cABMR) is the leading cause of late kidney transplant loss (after 1 year of kidney transplantation). Its therapeutic manage…
Chronic active antibody mediated rejection (CAMR) is a therapeutic challenge in transplant recipients that does not respond well to conventional treatments for…
Background: People who have lung transplants often survive 6 or 7 years. But some people develop donor-specific antibodies (DSA) after their transplants; antib…
In this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and then developed a condition called…